Happy Thursday, Investors: In a groundbreaking revelation, the clouds surrounding daily cannabis use are lifting, and leaving behind a stark warning. A recent study suggests that habitual consumption of cannabis might be more than just blowing off steam. Ir could be fanning the flames of increased risks for heart attacks and strokes.

Plus, an open-source psychedelic therapy learning framework? What is it all about?

Also, check out the newest episode of Cannabis Insider, also available on Apple and Spotify.*

Puff Pass: Did someone forward you this email? Click here to get automatically subscribed.

TOP STORY

How A Simple Handshake At Benzinga Conference Changed How Cannabis Companies Finance Their Businesses

Briefly: When CEOs Grigori Mikayelyan of Growcycle and Joseph Lustberg of Upwise Capital met at the Benzinga Cannabis Capital Conference last April, they did more than just exchange business cards.

What Happened: Mikayelyan and Lustberg's meeting at our conference sparked a deal that would change their operations. It was the genesis of Growcycle Financing, a venture that could only have been born in an environment where leaders discuss monumental industry shifts.

Why It Matters: Growcycle and Upwise Capital saw an opportunity to address a glaring need in the cannabis market: Access to capital. With traditional banking largely off-limits, their partnership is a lifeline for businesses starving for growth. This is a potential game-changer for companies learning to navigate the complexities of the industry.

Click here to read more

A MESSAGE FROM OUR PARTNERS

FIVE ZINGERS

Enveric Biosciences announces non-binding deals to license out three types of drug compounds

Green Thumb Industries' $278M Profits, margin and strategic insights Explained For Everyday Investors

Curaleaf price target spikes, fueled by German cannabis legalization changes — ROTH MKM Explains

Verano CEO says 'The Sky Is The Limit' for its 2024 achievements despite higher net loss QoQ

Zig-Zag rolling paper maker Turning Point reported a gross profit increased 1.9% to $50.5 million.

ONE FOR THE ROAD

All You Need To Know About The German Marijuana Market: Changes, Size And Leading Players

Briefly: Senior analyst Pablo Zuanic of Zuanic & Associates outlines the transformative potential of new legislation in Germany's medical cannabis sector.

So Basically: Zuanic forecasts market growth from a 28,000 patient base in 2023 to a value of €1.7 billion by 2025.

That Said: Zuanic emphasizes the nuanced reality behind Germany's cannabis "legalization," a gradual, phased approach to full legalization. The initial phase allows for the possession, home cultivation and social clubs, though retail sales remain off-limits, posing potential risks and benefits.

So Then: Zuanic's projections hinge on the assumption that 1% of Germany's roughly 85 million citizens will become medical marijuana cash payers, a stark increase from the current 0.03%.

So What? Zuanic also identifies Canadian cannabis giants Aurora and Tilray as well-positioned to benefit from the expected boom, given their strong export ties to Germany.

Click here to read the full report

A MESSAGE FROM OUR PARTNERS

KEEP READING

Before you go, be sure to subscribe to our other newsletters:

Ring The Bell: If you have to pick just one daily financial newsletter, it’s not a choice. Subscribe here.

The Street Sheet: A Wall Street cheat sheet, delivered every Sunday directly to your inbox. One-click subscribe here.

Future Finance: TradFi is tired. Wake up to the future of finance with this midday fintech and crypto letter. Subscribe here.

The Flag: Top takes from Washington to Wall Street impacting policy and your portfolio. One-click subscribe here.cannabis